MK-677 Capsules · 1 catalogue item
1Identification
| Product identifier | MK-677 — capsules |
|---|---|
| Catalogue items covered | MK-677 (Ibutamoren) (10mg/capsule) 60 Capsules PL-MK677-10MG-CAP |
| Synonyms / chemical names | MK-677: Ibutamoren (MK-677), ghrelin receptor agonist (mesylate as commonly supplied) (CAS 159752-10-0) |
| Recommended use | Laboratory research chemical for in-vitro and animal-model studies by trained personnel. |
| Restrictions on use | Not for human or veterinary use, diagnosis or therapy. Not for use as a drug, food, dietary supplement, cosmetic or in household products. Not for resale to the public for personal use. |
| Supplier | PrymaLab LLC (PrymaLab Analytical), 3705 Music Branch Rd, Ashland, KY 41102, United States · Tel. +1 (606) 465-9063 · michael@prymalab.net · https://prymalab.net |
| Emergency telephone | Poison Help (US, 24 h): 1-800-222-1222 · Supplier (business hours, US Eastern): +1 (606) 465-9063 |
2Hazard(s) identification
Classification of the mixture
Not classified as hazardous under OSHA HCS 2012 (29 CFR 1910.1200) or UN GHS Rev. 7.
None of the ingredients is present at or above the generic concentration limits that would classify the mixture (Section 3 lists the ingredient classifications and concentrations).
Label elements
No pictogram, signal word, hazard statement or precautionary statement is required. Recommended precautions: wear gloves, a laboratory coat and eye protection; avoid generating dust or aerosols; wash hands after handling; do not eat, drink or smoke in the laboratory.
Hazards not otherwise classified / other hazards
- Pharmacologically active material. Accidental injection, ingestion or absorption may produce systemic effects consistent with the compound's mechanism of action; see Section 11.
- The active ingredient(s) (< 10% of the mixture) have no acute toxicity data.
- Finely divided organic powder may form combustible dust concentrations in air if dispersed in bulk (not expected at laboratory scale).
3Composition / information on ingredients
Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle.
| Ingredient | CAS No. | Formula | Concentration | Quantity | Ingredient classification |
|---|---|---|---|---|---|
| MK-677 Ibutamoren (MK-677), ghrelin receptor agonist (mesylate as commonly supplied) | 159752-10-0 | C27H36N4O5S | 2.5% w/w of capsule contents (nominal) | 10 mg per capsule | Acute tox. oral 3 · H301 |
| Microcrystalline cellulose Microcrystalline cellulose (capsule filler) | 9004-34-6 | (C6H10O5)n | balance of capsule contents | — | not classified |
| Gelatin Gelatin (capsule shell) | 9000-70-8 | — | capsule shell | — | not classified |
Peptides are supplied as the acetate or trifluoroacetate salt unless stated otherwise; the counter-ion and residual water make up the balance of a lyophilized product. Concentration limits used for mixture classification follow OSHA HCS 2012 Appendix A. Concentrations of the active in the capsule contents are calculated for a nominal fill weight of 400 mg; the classification of the pure active substance is given in Section 11 for the case where capsule contents are handled as a powder.
4First-aid measures
| Inhalation | Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor. |
|---|---|
| Skin contact | Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice. |
| Eye contact | Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice. |
| Ingestion | Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell. |
| Most important symptoms and effects | No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption. |
| Indication of immediate medical attention | Treat symptomatically. Show this safety data sheet to the attending physician. No specific antidote is known. |
5Fire-fighting measures
| Suitable extinguishing media | Water spray, carbon dioxide, dry chemical or alcohol-resistant foam. Use measures appropriate to the surrounding fire. |
|---|---|
| Unsuitable extinguishing media | None known. Do not use a high-pressure water jet on powders (dust dispersion). |
| Specific hazards | Combustible organic solid; capsule contents may form combustible dust if dispersed in bulk. Thermal decomposition may release carbon monoxide, carbon dioxide and nitrogen oxides, and sulfur oxides. |
| Protective equipment for fire-fighters | Self-contained breathing apparatus and full protective clothing. Prevent run-off from entering drains. |
6Accidental release measures
| Personal precautions | Wear the protective equipment in Section 8. Keep unprotected people away. Avoid dust formation and inhalation of dust. |
|---|---|
| Environmental precautions | Do not allow material to reach drains, surface water or soil. Quantities supplied are small; collect for disposal. |
| Methods for cleaning up | Collect intact capsules. Dampen any spilled powder with water, wipe up with absorbent material and place in a sealed container for disposal. Decontaminate surfaces with 70% alcohol or detergent and water. |
7Handling and storage
| Precautions for safe handling | Do not open or crush capsules unless required for an experiment; if capsule contents are handled as a powder, avoid generating dust and weigh inside a ventilated enclosure. Wash hands after handling. Do not eat, drink or smoke in the handling area. |
|---|---|
| Conditions for safe storage | Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light. Keep the container tightly closed and labelled, out of reach of unauthorised persons. |
| Storage temperature | 15–25 °C, dry, protected from light |
| Incompatible materials | Strong oxidising agents, strong acids and bases. |
8Exposure controls / personal protection
| Occupational exposure limits | Microcrystalline cellulose: OSHA PEL 15 mg/m³ (total dust), 5 mg/m³ (respirable fraction); ACGIH TLV 10 mg/m³ (as cellulose). No occupational exposure limits have been established for the active ingredient(s). |
|---|---|
| Engineering controls | Good general laboratory ventilation. Weigh or manipulate dry powder in a ventilated enclosure (powder hood, biosafety cabinet or fume hood). An eyewash station should be available. |
| Eye / face protection | Safety glasses with side shields (ANSI Z87.1 / EN 166). |
| Skin protection | Nitrile gloves (inspect before use; change after contamination) and a laboratory coat. |
| Respiratory protection | Not normally required with the engineering controls above. Where dust cannot be controlled, use a NIOSH-approved N95 (or P2) particulate respirator. |
| Hygiene measures | Wash hands after handling and before breaks. Remove contaminated clothing. Do not pipette by mouth. |
9Physical and chemical properties
| Physical state / appearance | Solid. Hard gelatin capsules containing a white to off-white powder. |
|---|---|
| Odour / odour threshold | Characteristic (Cayman) |
| pH | Not applicable (solid) |
| Melting / freezing point | Undetermined (Cayman); no data (ChemicalBook) |
| Boiling point | No data available |
| Flash point / flammability | Not applicable (non-flammable solid); combustible organic material |
| Vapour pressure / density | Negligible (solid) |
| Relative density | No data available (bulk density of lyophilized cake is low) |
| Solubility | Mesylate: DMF 25 mg/mL; DMSO 25 mg/mL; ethanol 10 mg/mL; PBS (pH 7.2) 10 mg/mL (Cayman); water 5 mg/mL clear (ChemicalBook); DMSO 252.5 mg/mL (TargetMol). Free base: water soluble (Cayman 44475) |
| Partition coefficient (log Pow) | No data available |
| Auto-ignition / decomposition temperature | No data available; peptides decompose above about 200 °C |
| Molecular formula / mass | MK-677: C27H36N4O5S, 528.7 g/mol |
| Other information | Mesylate salt C27H36N4O5S . CH4O3S, MW 624.8, CAS 159752-10-0; free base C27H36N4O5S, MW 528.7, CAS 159634-47-6, density 1.32 g/cm3 (Cayman). Not flammable. |
10Stability and reactivity
| Reactivity | No hazardous reactivity under normal laboratory conditions. |
|---|---|
| Chemical stability | Stable when stored as recommended (Section 7). Lyophilized peptides are hygroscopic and degrade faster once moist or reconstituted. |
| Possibility of hazardous reactions | None known. |
| Conditions to avoid | Heat, direct light, moisture, repeated freeze–thaw cycles. |
| Incompatible materials | Strong oxidising agents, strong acids and bases. |
| Hazardous decomposition products | Carbon oxides and nitrogen oxides, sulfur oxides on combustion. No hazardous decomposition under recommended storage. |
11Toxicological information
Likely routes of exposure: Ingestion; inhalation of dust and skin/eye contact if capsules are opened.
Symptoms related to the physical, chemical and toxicological characteristics: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.
MK-677 Ibutamoren (MK-677), ghrelin receptor agonist (mesylate as commonly supplied) · CAS 159752-10-0
Substance classification adopted: Acute tox. oral 3 · H301
Cayman Chemical SDS for ibutamoren free base (oral LD50 100 mg/kg, Acute Tox. 3). The mesylate SDS classification H300, derived from a dog TDLo rather than an LD50, is not adopted.
| Acute toxicity, oral | Cayman 18003 (mesylate): oral TDLo 1 mg/kg (dog) - used by Cayman as basis for Category 1; Cayman 44475 (free base): oral LD50 100 mg/kg (species not stated) - Category 3; ChemicalBook: no data available. Bimeda-type ATE not available. |
|---|---|
| Acute toxicity, dermal | No data available |
| Acute toxicity, inhalation | No data available |
| Skin corrosion/irritation | No irritant effect (Cayman) |
| Serious eye damage/irritation | No irritating effect (Cayman) |
| Respiratory or skin sensitisation | No sensitizing effects known (Cayman) |
| Germ cell mutagenicity | No data available |
| Carcinogenicity | Not listed by IARC, NTP or OSHA |
| Reproductive toxicity | No data available (GH secretagogue; see notes) |
| STOT, single exposure | No data available |
| STOT, repeated exposure | Subcutaneous TDLo 300 mg/kg (rat) (Cayman 18003); clinical trials: increased appetite, edema, insulin resistance/raised fasting glucose, congestive heart failure signal in elderly hip-fracture trial |
| Aspiration hazard | No data available |
- Ghrelin receptor agonist (growth hormone secretagogue). WADA Prohibited List class S2.
Mixture classification: the ingredient classifications above were combined using the additivity and cut-off rules of OSHA HCS 2012 Appendix A (acute toxicity estimate calculation; 10% cut-off for skin and eye irritation; 0.1% for carcinogenicity, reproductive toxicity and respiratory sensitisation; 1.0% for skin sensitisation and STOT; 20% for respiratory tract irritation).
Carcinogen listings: no ingredient is listed as a carcinogen by IARC, NTP or OSHA.
12Ecological information
MK-677: No ecotoxicity data available. Cayman water hazard class 1 (self-assessment): slightly hazardous for water.
Persistence and degradability: peptides and amino acids are expected to biodegrade readily; benzyl alcohol is readily biodegradable (92–96% in 14 days, OECD 301C). Bioaccumulative potential: low (hydrophilic, log Pow < 3 where known). Mobility in soil: water-soluble; mobile. PBT/vPvB: not expected to meet the criteria. Other adverse effects: none known. Do not release concentrated material to the environment.
13Disposal considerations
Dispose of unused material and contaminated packaging through a licensed chemical-waste contractor in accordance with federal (40 CFR 261), state and local regulations; the material is not a listed RCRA hazardous waste. Do not pour down the drain. Small residues may be inactivated with 10% bleach for 30 minutes before disposal where local rules allow. Empty glass vials and cartridges: remove labels or deface them before recycling or disposal.
14Transport information
| DOT (49 CFR) / IATA / IMDG | Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used. |
|---|---|
| UN number / proper shipping name / class / packing group | Not applicable. |
15Regulatory information
| OSHA Hazard Communication Standard (29 CFR 1910.1200) | Not classified as hazardous. This sheet is provided voluntarily. |
|---|---|
| TSCA (Toxic Substances Control Act) | MK-677: not listed on the TSCA Inventory (supplied for research and development; 40 CFR 720.36); Microcrystalline cellulose: listed on the TSCA Inventory; Gelatin: listed on the TSCA Inventory. |
| SARA Title III (Sections 302, 311/312, 313), CERCLA | No ingredient is listed as an extremely hazardous substance (Section 302), a Section 313 toxic chemical or a CERCLA hazardous substance. |
| California Proposition 65 | No ingredient is listed as known to the State of California to cause cancer or reproductive toxicity. |
| State right-to-know lists | No ingredient is listed. |
| US FDA | Research chemical. Not an FDA-approved drug product; not evaluated for safety or efficacy in humans or animals; not GRAS; not a dietary ingredient. Sold for laboratory research use only. |
| US DEA controlled substances | No ingredient is scheduled under the Controlled Substances Act at the revision date. |
| Anti-doping (information only) | MK-677: WADA Prohibited List, class S2. |
| International | The classification in Section 2 applies equally under EU CLP (Regulation (EC) 1272/2008) and other UN GHS implementations; peptides of this kind are generally not registered under REACH (research and development use). |
16Other information
| Revision | Revision 1.0, October 3, 2026 — first issue. Prepared by PrymaLab Analytical, PrymaLab LLC. |
|---|---|
| Classification method | Calculated from the ingredient classifications (Section 3) with the OSHA HCS 2012 Appendix A mixture rules; ingredient classifications were adopted from the supplier safety data sheets listed below with the PrymaLab policy adjustments stated in Section 11. Policy: Cayman Chemical is the primary reference for research peptides and novel small molecules and Sigma-Aldrich/Merck for commodity chemicals; a more conservative manufacturer or ECHA classification is adopted where internally consistent; SARMs, GLP-1 receptor agonists, GnRH analogues and gonadotropins carry reproductive-toxicity classifications by expert judgement. Concentrations of the active in the capsule contents are calculated for a nominal fill weight of 400 mg; the classification of the pure active substance is given in Section 11 for the case where capsule contents are handled as a powder. |
| Sources consulted | Cayman Chemical; ChemicalBook MSDS; TargetMol product page; Spectrum Chemical; Sigachi Industries; Parchem; Fisher Scientific / Acros Organics; Electron Microscopy Sciences. |
| Abbreviations | ATE acute toxicity estimate · CAS Chemical Abstracts Service · GHS Globally Harmonized System · HCS Hazard Communication Standard · IARC International Agency for Research on Cancer · LD50/LC50 median lethal dose/concentration · NTP National Toxicology Program · OEL occupational exposure limit · PEL permissible exposure limit · STOT specific target organ toxicity · TLV threshold limit value · WADA World Anti-Doping Agency. |
